Article - 15/01/2009 Felicitas Pröls – an all-rounder in anatomy Plant research molecular developmental biology and cell biology anatomy these are just a few of the fields in which Prof. Dr. Felicitas Pröls from the University of Freiburg has achieved major success. She has also recently begun looking into molecular neurobiology. For me professional diversity is the most important thing and it is also the reason why I am happy with my chosen profession said the researcher. https://www.gesundheitsindustrie-bw.de/en/article/news/felicitas-proels-an-all-rounder-in-anatomy
Press release - 15/01/2009 Nycomed strengthens its osteoporosis portfolio Nycomed and EffRx today announced a licensing agreement on EffRx' drug EX101 (effervescent alendronate) for the treatment of osteoporosis. Under the agreement, Nycomed will receive the exclusive rights to develop, manufacture and commercialise the effervescent formulation of alendronate for the treatment of osteoporosis in a large number of countries worldwide. EX101 presents a significant enhancement to Nycomed's osteoporosis…https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-strengthens-its-osteoporosis-portfolio
Article - 14/01/2009 From old to new – the path to the next generation of antibiotics When they were first discovered antibiotics were seen as miracle cures. The perception of antibiotics has not greatly changed since. No other class of drugs has ever been able to double the average life expectancy in such a short time. However there is a huge risk that the success that has been achieved will come to nothing because a growing number of pathogens are becoming resistant to antibiotics.https://www.gesundheitsindustrie-bw.de/en/article/news/from-old-to-new-the-path-to-the-next-generation-of-antibiotics
Dossier - 14/01/2009 Biopharmaceuticals continue their triumphant success The first genetically engineered drug entered the market a little over 25 years ago. Since then more than 100 others have been launched. Many of these biopharmaceuticals have an outstanding effect thus revolutionising the therapeutic options available in many medical sectors. Biopharmaceuticals also have a huge economic potential. The huge potential of these innovative drugs and their importance for Germanys pharmaceutical industry is reflected…https://www.gesundheitsindustrie-bw.de/en/article/dossier/biopharmaceuticals-continue-their-triumphant-success
Press release - 14/01/2009 Hunters of lost treasures On 1st December 2008 Prof. Dr. Karl Schmid the first person to hold the F.W. Schnell Foundations endowed professorship for crop biodiversity and breeding informatics started the ball rolling on a unique European-wide project. Schmid and his colleagues are searching gigantic databases in which genetic analyses and plant descriptions are stored for hidden treasures. https://www.gesundheitsindustrie-bw.de/en/article/press-release/hunters-of-lost-treasures
Article - 14/01/2009 Strict requirements for the market approval of tissue engineering products New regulations for the marketing approval of advanced therapy medicinal products have applied in the EU since December 2008. Prof. Sabine Kloth from TÜV SÜD Product Service GmbH is an expert in materials of animal origin and has been closely following the formulation of the ATMP Regulation. https://www.gesundheitsindustrie-bw.de/en/article/news/strict-requirements-for-the-market-approval-of-tissue-engineering-products
Press release - 14/01/2009 Looking for the Achilles’ heel of parasites Researchers have identified a hormone that controls whether nematode larvae turn into parasites or not.https://www.gesundheitsindustrie-bw.de/en/article/press-release/looking-for-the-achilles-heel-of-parasites
Press release - 14/01/2009 IND Approval for CureVac CureVac Receives IND Approval from the FDA to start its Phase I/IIa mRNA Vaccine Clinical Trial in Prostate Cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/ind-approval-for-curevac
Press release - 11/01/2009 Merckle’s empire collapse leads to sale of ratiopharm It was clear that something was amiss in 2008, and now things are clearer: The Ulm-based generics producer ratiopharm is to be sold in order to save the Merckle empire that has run into difficulties in the global financial crisis. Numerous sources report that the pharmaceutical company will not be sold before 2010 due to the current unfavourable market situation. It is not known whether the Merckle group will have to part with other companies in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/merckle-s-empire-collapse-leads-to-sale-of-ratiopharm
Press release - 11/01/2009 Killing cancer cells with only limited side effects A group of clinical researchers at the University Hospital in Ulm has discovered new ways to specifically kill cancer cells with radioactive irradiation while preventing healthy organs from being affected. The researchers have also discovered that this method breaks the chemoresistance of cancer cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/killing-cancer-cells-with-only-limited-side-effects
Press release - 11/01/2009 What have sunscreens got to do with hormones? Most people are well aware that sunbathing can have dangerous consequences. In Switzerland the debate concerning the undesirable side effects of sunscreens has been temporarily put on hold but will most likely start up again with the onset of the winter season. Daniel R. Dietrich chair of the Department of Toxicology at the University of Constance gives us more details in the following interview.https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-have-sunscreens-got-to-do-with-hormones
Press release - 10/01/2009 Supporting equal opportunities for women at universities in Baden-Württemberg The Baden-Württemberg government now brings together information regarding equal opportunities as well as “Girls and Technology” projects at the state’s universities on the www.scientifica.de Internet portal. https://www.gesundheitsindustrie-bw.de/en/article/press-release/supporting-equal-opportunities-for-women-at-universities-in-baden-wuerttemberg
Article - 10/01/2009 Julia Kirchheiner searches for drugs for individuals Drugs for individuals rather than diseases - thats what Julia Kirchheiner from the University of Ulm is striving for. The 37-year-old is one of only a handful German experts working in pharmacogenetics research a field of research that investigates the genetic causes of individual differences in peoples response to drugs. https://www.gesundheitsindustrie-bw.de/en/article/news/julia-kirchheiner-searches-for-drugs-for-individuals
Article - 09/01/2009 Kay Diederichs – important insights in the fight against bacterial antibiotics resistance Bacteria will always find ways to defend themselves against substances such as antibiotics, thus inhibiting their effect. Many bacteria have pump systems that they use to actively remove antibiotic drugs from the cell. Prof. Kay Diederichs at the University of Constance is working on the elucidation of these mechanisms in order to produce useful information for the development of bacterial pump inhibitors. https://www.gesundheitsindustrie-bw.de/en/article/news/kay-diederichs-important-insights-in-the-fight-against-bacterial-antibiotics-resistance
Press release - 09/01/2009 Richter to succeed Siegenführ Dr. Michael Richter is the new German BioValley/Freiburg Bioregion coordinator. He succeeds Dr. Thea Siegenführ who has shaped and skilfully organised the biotechnology landscape on the Upper Rhine for the last 16 years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/richter-to-succeed-siegenfuehr
Press release - 08/01/2009 ILM – Cell biology, molecular biology, histology The ILM uses cell biology, molecular biology and histological methods to investigate the effects of photosensitisers and laser irradiation on cells and tissues.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-cell-biology-molecular-biology-histology
Press release - 08/01/2009 ILM – 3D measurement technique The ILM applies a broad range of different methods to determine the form and shape of objects, including 3D surface acquisition using stripe projection-based imaging, interferometry and optical coherence interferometry (OCT)https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-3d-measurement-technique
Press release - 08/01/2009 ILM – In-line determination of roughness in paper production An important parameter for the printability of paper is its microstructure and roughness. Previous approaches used to identify these parameters were limited to individual quality controls in the laboratory; no technology has so far been available for process-integrated sensoring. The ILM has taken on the task of solving this issue.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-in-line-determination-of-roughness-in-paper-production
Press release - 08/01/2009 ILM – Molecular cytogenetic diagnostics The ILM used multicolour fluorescence in-situ hybridisation for the detection of chromosomal changes in the vein tissue of patients suffering from recurrent varicosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-molecular-cytogenetic-diagnostics
Press release - 08/01/2009 ILM – Laser Therapy Centre The study carried out by the ILM investigates the fractional irradiation of wrinkles and scars using an Erbium:YAG handpiece.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-laser-therapy-centre
Press release - 08/01/2009 ILM – Spectroscopic characterisation of substances The optical characterisation of materials through transmission, absorption and reflection is only complete when these values can also be indicated in dependence of the wavelength. In order to investigate these wavelength dependencies, the ILM has a number of high-quality spectrometers available that cover the entire range from ultraviolet to infrared light.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-spectroscopic-characterisation-of-substances
Press release - 08/01/2009 ILM – Radiobiology and biological dosimetry II Lasers, in particular holmium-Yag and dye lasers are being used to an increasing extent in urology to destroy kidney stones. In order to obtain a better understanding of the mechanism of action, detailed investigations were carried out in cooperation with the Laser Centre in Munich.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-radiobiology-and-biological-dosimetry-ii
Press release - 08/01/2009 ILM – Laser-assisted diagnosis and therapy method for chronic wounds The goal of the cooperative project of the Competence Centre for Minimally Invasive Medicine & Technology Tübingen-Tuttlingen (MITT) and the University Hospital of Tübingen was to facilitate the treatment of chronic wounds and improve their healing process using an innovative laser method. The partners developed a method that enables the recognition of necrotic tissue on wound surfaces and the contact-free ablation of the tissue using a…https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-laser-assisted-diagnosis-and-therapy-method-for-chronic-wounds
Press release - 08/01/2009 ILM – Optical analytics In collaboration with the company Labor Dr. Merk & Kollegen GmbH and the Institute of Virology at the University of Ulm, the ILM is developing an innovative detection system for the early diagnosis of influenza virus infections in pharyngeal secretions.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-optical-analytics
Press release - 08/01/2009 ILM – Bioactive interfaces It is particularly important to consider the biocompatibility of material interfaces. For example, implant materials with a surface composition that favours cell growth have a decisive advantage. However there are other cases where biophobic material characteristics might be more suitable. For example, specifically modifying the surface of surgical metals might prevent pathogens from attaching and could also make the cleaning and deactivation of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-bioactive-interfaces